Related Experiment Video
Updated: Aug 15, 2026

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Androgen receptor and TGFbeta1/Smad signaling are mutually inhibitory in prostate cancer
1Department Urology, Netherlands Cancer Institute, Amsterdam. h.vd.poel@nki.nl
Purpose:
The androgen receptor (AR) has been reported to modulate TGFbeta1/Smad signaling and is, like transforming growth factor beta 1 (TGFbeta1) often overexpressed in hormone refractory prostate cancer (HRPC). In human prostate cancer cell lines the role of AR in the response to TGFbeta1 is evaluated.
Material And Methods:
PC3 cells grow hormone independently, lack AR expression, and have a functioning TGFbeta1/Smad signaling cascade whereas LNCaP cells express (a mutated) AR, and lack TGFbeta receptor (TGFbetaR2) expression. Luciferase reporter assays for AR signaling, TGFbeta1/Smad signaling, and E2F transcriptional activity were performed. PC3 cells and TGFbetaR2 stably-transfected LNCaP cells (LNCaP-R2) were incubated with dihydrotestosterone (DHT), or TGFbeta1. Wst-1 assay and flowcytometric evaluation of annexin-V staining were applied to quantify cell growth and apoptosis. Immunoblot analysis was performed to evaluate c-Myc expression.
Results:
Luciferase reporter assays showed mutual transcriptional inhibition of AR and TGFbeta/Smad signaling in AR transfected PC3 and LNCaP-R2 cells. AR expression reduced the TGFbeta1/Smad transcriptional activity and the growth inhibitory effects of TGFbeta1 also in the absence of DHT in PC3 cells. TGFbeta1 reduced the E2F transcriptional activity of AR activation by DHT. This was associated with a reduced c-Myc expression in PC3 cells. AR expression in PC3 cells prevented TGFbeta1 induced growth inhibition and apoptosis.
Conclusion:
AR overexpression is an effective way of hormone refractory prostate cancer cells to overcome the growth inhibitory effects of elevated serum TGFbeta1 levels even in the absence of DHT. These findings provide an explanation for how AR overexpression favors growth in HRPC.
Insights
Androgen receptor (AR) overexpression in hormone refractory prostate cancer (HRPC) cells helps them overcome growth inhibition from transforming growth factor beta 1 (TGFbeta1). This explains how AR supports HRPC growth, even without DHT.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Androgen receptor (AR) and transforming growth factor beta 1 (TGFbeta1) signaling are often overexpressed in hormone refractory prostate cancer (HRPC).
- AR is known to modulate TGFbeta1/Smad signaling pathways.
Purpose of the Study:
- To evaluate the role of AR in the response to TGFbeta1 in human prostate cancer cell lines.
- To understand the interplay between AR and TGFbeta1/Smad signaling in HRPC.
Main Methods:
- Utilized PC3 (AR-negative) and LNCaP-R2 (AR-expressing) prostate cancer cell lines.
- Performed luciferase reporter assays for AR, TGFbeta1/Smad, and E2F activity.
- Assessed cell growth, apoptosis, and c-Myc expression following treatment with dihydrotestosterone (DHT) or TGFbeta1.
Main Results:
- AR and TGFbeta1/Smad signaling mutually inhibited each other transcriptionally.
- AR expression reduced TGFbeta1/Smad activity and TGFbeta1's growth-inhibitory effects, independent of DHT.
- TGFbeta1 reduced AR-mediated E2F activity and c-Myc expression, but AR expression prevented TGFbeta1-induced growth inhibition and apoptosis.
Conclusions:
- AR overexpression enables HRPC cells to resist TGFbeta1-induced growth inhibition, even with elevated TGFbeta1 levels and without DHT.
- This mechanism provides a rationale for AR's role in promoting HRPC progression.
Related Concept Videos
TGF - β Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amplifying Signals via Enzymatic Cascade
Hedgehog Signaling Pathway
The JAK-STAT Signaling Pathway

